| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Profit before tax | -11.6 | -10.3 |
| Net income | -11.6 | -8.7 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: VTVT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
vTv Therapeutics Inc.: key numbers
- Share price
- $17.69Close, Nov 16
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from vTv Therapeutics Inc.
All →vTv Therapeutics Financial Results
vTv Therapeutics reported third quarter 2026 financial results and provided a corporate update, highlighting the completion of enrollment for its Phase 3 CATT1 trial of cadisegliatin in type 1 diabetes. The company also announced that the FDA granted Orphan Drug Designation to HPPD for sickle cell disease and expects its current cash position to fund operations through the mid-2027 CATT1 topline data readout.
“Completing enrollment in the Phase 3 CATT1 trial is a significant milestone for vTv, and we look forward to reporting topline results in mid 2027.”
Paul Sekhri, Chairman, President and Chief Executive Officer
“The FDA recently granted Orphan Drug Designation for HPPD, which has shown promising activity in preclinical models of sickle cell disease. This designation strengthens our ability to advance partnering discussions for this program and provides another opportunity to create value for shareholders.”
Paul Sekhri, Chairman, President and Chief Executive Officer